Back to AZNCFView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
4 competitors in Paroxysmal Nocturnal Hemoglobinuria
View Full LandscapeDrug Information
Target Indication
Paroxysmal Nocturnal Hemoglobinuria
Clinical Trial
NCT06449001Last updated: 10/2/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/19/2024
Voydeya
Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia
OrphanPRIME
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
propranololPhase 3
Migraine Without Aura
Quetiapine SRPhase 3
Anxiety Disorders
Ceftaroline fosamilPhase 3
Infections
Erlotinib 150/100 mgPhase 3
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Ticagrelor orodispersible tabletsPhase 3
ST Elevation Myocardial Infarction
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts